About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 247345, 7 pages
http://dx.doi.org/10.1155/2013/247345
Clinical Study

Behcet’s Disease: Systemic and Ocular Manifestations

1Department of Ophthalmology, Clinical Centre of Belgrade, Pasterova 2, Belgrade 11000, Serbia
2Uvea Center, Center for Diagnostic and Treatment of Uveitis, Kneza od Semberije 14, Belgrade 11000, Serbia

Received 8 June 2013; Accepted 2 September 2013

Academic Editor: Fernando M. Penha

Copyright © 2013 Jelena Paovic et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Behcet, “Uber rezidivierende aphthose, durch ein virus verursachte geschwure am mund, am auge und an den genitalien,” Dermatologische Wochenschrift, vol. 105, pp. 1152–1157, 1937.
  2. International Team for the Revision of the International Criteria for Behçet's Disease (ITR-ICBD), “The international criteria for Behçet's disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria,” Journal of the European Academy of Dermatology and Venereology, 2013. View at Publisher · View at Google Scholar
  3. P. McCluskey and P. R. J. Powell, “The eye in systemic inflammatory diseases,” The Lancet, vol. 364, no. 9451, pp. 2125–2133, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Evereklioglu, “Managing the symptoms of Behçet's disease,” Expert Opinion on Pharmacotherapy, vol. 5, no. 2, pp. 317–328, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. F. Davatchi, F. Shahram, C. Chams, H. Chams, and A. Nadji, “Behçet's disease,” Acta Medica Iranica, vol. 43, no. 4, pp. 233–242, 2005. View at Scopus
  6. C. Evereklioglu, “Current concepts in the etiology and treatment of Behçet disease,” Survey of Ophthalmology, vol. 50, no. 4, pp. 297–350, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Altenburg, N. Papoutsis, H. Orawa, P. Martus, L. Krause, and C. C. Zouboulis, “Epidemiology and clinical manifestations of adamantiades-Behçet disease in Germany—current pathogenetic concepts and therapeutic possibilities,” Journal of the German Society of Dermatology, vol. 4, no. 1, pp. 49–66, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. D. Mendes, M. Correia, M. Barbedo et al., “Behçet's disease—a contemporary review,” Journal of Autoimmunity, vol. 32, no. 3-4, pp. 178–188, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. I. Krause and A. Weinberger, “Behçet's disease,” Current Opinion in Rheumatology, vol. 20, no. 1, pp. 82–87, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. U. Pleyer, D. Haziolan, S. Winterhalter, and N. Stuebiger, “Behçet's disease—ophthalmological and general aspects part I : etiology, pathogenesis and diagnostics,” Ophthalmologe, vol. 109, no. 11, pp. 1129–1141, 2012. View at Publisher · View at Google Scholar
  11. G. Hatemi, E. Seyahi, I. Fresko, and V. Hamuryudan, “Behcet’s syndrome: a critical digest of the recent literature,” Clinical and Experimental Rheumatology, vol. 30, no. 3, supplement 72, pp. S80–S89, 2012.
  12. K. Nakae, F. Masaki, T. Hashimoto, G. Inaba, M. Moshiziki, and T. Sakane, “Recent epidemiological features of Behcet’s disease in Japan,” in Behcet’s Disease, P. Godeau and B. Wechsler, Eds., pp. 145–151, Elsevier Science, 1993.
  13. F. Shahram, A. Nadji, A.-R. Jamshidi et al., “Behcet's disease in Iran, analysis of 5,059 cases,” Archives of Iranian Medicine, vol. 7, no. 1, pp. 9–14, 2004. View at Scopus
  14. F. Davatachi, F. Sharam, F. Gharibdoost, M. Alkbarian, A. Nadji Chams C, and H. Chams, “Clinical manifestations of Behcet’s disease in Iran: Behcet’s disease. Analysis of 2806 Cases,” Arthritis & Rheumatism, supplement 391, 1995.
  15. A. Gürler, A. Boyvat, and Ü. Türsen, “Clinical Manifestations of Behçet's disease: an analysis of 2147 patients,” Yonsei Medical Journal, vol. 38, no. 6, pp. 423–427, 1997. View at Scopus
  16. U. Tursen, A. Gurler, and A. Boyvat, “Evaluation of clinical findings according to sex in 2313 Turkish patients with Behçet's disease,” International Journal of Dermatology, vol. 42, no. 5, pp. 346–351, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. I. Tugal-Tutkun, S. Onal, R. Altan-Yaycioglu, H. Huseyin Altunbas, and M. Urgancioglu, “Uveitis in Behçet disease: an analysis of 880 patients,” American Journal of Ophthalmology, vol. 138, no. 3, pp. 373–380, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. T. Sakane, M. Takeno, N. Suzuki, and G. Inaba, “Behcet's disease,” The New England Journal of Medicine, vol. 341, no. 17, pp. 1284–1291, 1999. View at Publisher · View at Google Scholar · View at Scopus
  19. N. Ohguro, K. H. Sonoda, M. Takeuchi, M. Matsumara, and M. Mochizuku, “The 2009 prospective multi-center epidemiologic survey of uveitis in Japan,” Japanese Journal of Ophthalmology, vol. 56, no. 5, pp. 432–435, 2012. View at Publisher · View at Google Scholar
  20. M. H. Houman, H. Neffati, A. Braham et al., “Behçet's disease in Tunisia demographic, clinical and genetic aspects in 260 patients,” Clinical and Experimental Rheumatology, vol. 25, no. 4, pp. S58–S64, 2007. View at Scopus
  21. M. Muhaya, S. Lightman, E. Ikeda et al., “Behçet's disease in Japan and in great Britain: a comparative study,” Ocular Immunology and Inflammation, vol. 8, no. 3, pp. 141–148, 2000.
  22. C. C. Zouboulis, “Epidemiology of adamantiades-Behcet's disease,” Annales de Medecine Interne, vol. 150, no. 6, pp. 488–498, 1999. View at Scopus
  23. T. Akpolat, Y. Koç, I. Yeniay et al., “Familial Behçet's disease,” The European Journal of Medicine, vol. 1, no. 7, pp. 391–395, 1992. View at Scopus
  24. N. Mizuki, H. Inoko, and S. Ohno, “Pathogenic gene responsible for the predisposition to Behcet's disease,” International Reviews of Immunology, vol. 14, no. 1, pp. 33–48, 1997. View at Scopus
  25. N. Mizuki, M. Ota, Y. Katsuyama et al., “HLA-B*51 allele analysis by the PCR-SBT method and a strong association of HLA-B*5101 with Japanese patients with Behçet's disease,” Tissue Antigens, vol. 58, no. 3, pp. 181–184, 2001. View at Publisher · View at Google Scholar · View at Scopus
  26. I. T. Kaya, “Genetics of Behcet’s disease,” Pathology Research International, vol. 2012, Article ID 912589, 6 pages, 2012. View at Publisher · View at Google Scholar
  27. D. J. Kilmartin, A. Finch, and R. W. Acheson, “Primary association of HLA-B51 with Behçet's disease in Ireland,” British Journal of Ophthalmology, vol. 81, no. 8, pp. 649–653, 1997. View at Scopus
  28. M. De Menthon, M. P. LaValley, C. Maldini, L. Guillevin, and A. Mahr, “HLA-B51/B5 and the risk of Behçet's disease: a systematic review and meta-analysis of case-control genetic association studies,” Arthritis Care and Research, vol. 61, no. 10, pp. 1287–1296, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. N. Mizuki and S. Ohno, “Immunogenetic studies of Behcet's disease,” Revue du Rhumatisme (English Edition), vol. 63, no. 7-8, pp. 520–527, 1996. View at Scopus
  30. N. Mizuki, M. Ota, Y. Katsuyama et al., “HLA-B*51 allele analysis by the PCR-SBT method and a strong association of HLA-B*5101 with Japanese patients with Behçet's disease,” Tissue Antigens, vol. 58, no. 3, pp. 181–184, 2001. View at Publisher · View at Google Scholar · View at Scopus
  31. S.-H. Park, K.-S. Park, Y.-I. Seo et al., “Association of MICA polymorphism with HLA-B51 and disease severity in korean patients with Behcet's disease,” Journal of Korean Medical Science, vol. 17, no. 3, pp. 366–370, 2002. View at Scopus
  32. H. Direskeneli, “Behçet's disease: infectious aetiology, new autoantigens, and HLA-B51,” Annals of the Rheumatic Diseases, vol. 60, no. 11, pp. 996–1002, 2001. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Guel, “Behcet’s disease: an update on the pathogenesis,” Clinical and Experimental Rheumatology, vol. 19, supplement 24, pp. S6–S12, 2001.
  34. N. Kitaichi, A. Miyazaki, M. R. Stanford, H. Chams, D. Iwata, and S. Ohno, “Ocular features of Behçet's disease: an international collaborative study,” British Journal of Ophthalmology, vol. 91, no. 12, pp. 1579–1582, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Takeuchi, H. Hokama, R. Tsukahara et al., “Risk and prognosis factors of poor visual. outcome in Behcet’s disease with ocular involvement,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 243, no. 11, pp. 1147–1152, 2005.
  36. K. Durrani, M. Ahmed, and C. S. Foster, “Adamantiades-Behcet disease: diagnosis and current concepts in management of ocular manifestations,” Comprehensive Ophthalmology Update, vol. 8, no. 4, pp. 225–233, 2007. View at Scopus
  37. C. Evereklioglu, “Current concepts in the etiology and treatment of Behçet disease,” Survey of Ophthalmology, vol. 50, no. 4, pp. 297–350, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Dias Ljopis, M. Cervera, and J. l. Mnezo, “Cyclosporin A treatment of Behcet’s disease: a long—term study,” Current Eye Research, vol. 9, pp. 17–23, 1990.
  39. H. Yazisi, H. Pazarli, C. G. Barnes, et al., “A controlled trial of azathioprine in Behcet’s syndrome,” The New England Journal of Medicine, vol. 322, pp. 281–285, 1997.
  40. V. Humuryudan, Y. Ozyazgan, N. Hizli, et al., “Azathioprine in Behcet’s syndrome,” Arthritis and Rheumatism, vol. 40, pp. 760–774, 1997.
  41. A. J. Greenwood, M. R. Stanford, and E. M. Graham, “The role of azathioprine in the management of retinal vasculitis,” Eye, vol. 12, no. 5, pp. 783–788, 1998. View at Scopus
  42. V. G. Kaklamani and P. G. Kaklamanis, “Treatment of behçet's disease—an update,” Seminars in Arthritis and Rheumatism, vol. 30, no. 5, pp. 299–312, 2001. View at Publisher · View at Google Scholar · View at Scopus
  43. C. Mat, S. Yurdakul, S. Uysal et al., “A double-blind trial of depot corticosteroids in Behçet's syndrome,” Rheumatology, vol. 45, no. 3, pp. 348–352, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. C. M. Deuter, M. Zierhut, D. Doycheva, and I. Kötter, “Treatment of Behcet’s disease yesterday and today,” Ophthalmologe, vol. 109, no. 6568, 74 pages, 2012.
  45. U. Pleyer, D. Hazirolan, S. Winterhalter, and N. Stubiger, “Behcet’s disease-ophthalmological and general aspects: part 2: therapy,” Ophthalmologe, vol. 110, no. 3, pp. 273–284, 2013.
  46. P. P. Sfikakis, N. Markomichelakis, E. Alpsoy et al., “Anti-TNF therapy in the management of Behçet's disease—review and basis for recommendations,” Rheumatology, vol. 46, no. 5, pp. 736–741, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. S. Sugita, Y. Kawazoe, A. Imai, Y. Yamada, S. Horie, and M. Mochizuki, “Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Behcet's disease,” Arthritis Research & Therapy, vol. 14, article R99, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. T. Sakai, H. Watanabe, K. Kuroyanagi et al., “Health- and vision-related quality of life in patients receiving infliximab therapy for Behcet uveitis,” British Journal of Ophthalmology, vol. 97, no. 3, pp. 338–342, 2013.
  49. S. Furuta, Y. W. Chow, A. N. Chaudhry, and D. Jayne, “Switching of anti-TNF-α agents in Behcet’s disease,” Clinical and Experimental Rheumatology, vol. 30, no. 3, supplement 72, pp. S62–S68, 2012.
  50. E. W. Lindstedt, G. S. Baarsma, R. W. A. M. Kuijpers, and P. M. Van Hagen, “Anti-TNF-α therapy for sight threatening uveitis,” British Journal of Ophthalmology, vol. 89, no. 5, pp. 533–536, 2005. View at Publisher · View at Google Scholar · View at Scopus
  51. P. P. Sfikakis, P. H. Kaklamanis, A. Elezoglou et al., “Infliximab for recurrent, sight-threatening ocular inflammation in adamantiades-Behçet disease,” Annals of Internal Medicine, vol. 140, no. 5, pp. 404–406, 2004. View at Scopus
  52. M. Accorinti, M. P. Pirraglia, M. P. Paroli, R. Priori, F. Conti, and P. Pivetti-Pezzi, “Infliximab treatment for ocular and extraocular manifestations of Behçet's disease,” Japanese Journal of Ophthalmology, vol. 51, no. 3, pp. 191–196, 2007. View at Publisher · View at Google Scholar · View at Scopus
  53. P. P. Sfikakis, P. G. Theodossiadis, C. G. Katsiari, P. Kaklamanis, and N. N. Markomichelakis, “Effect of infliximab on sight-threatening panuveitis in Behçet's disease,” The Lancet, vol. 358, no. 9278, pp. 295–296, 2001. View at Publisher · View at Google Scholar · View at Scopus
  54. C. Briani, A. Doria, R. Marcolongo et al., “Increased titres of IgM anti-heparan sulfate antibody in Behçet's disease,” Clinical and Experimental Rheumatology, vol. 24, no. 5, pp. S104–S107, 2006. View at Scopus
  55. T. Ilknur, U. Pabuççuoglu, C. Akin, B. Lebe, and A. T. Gunes, “Histopathologic and direct immunofluorescence findings of the papulopustular lesions in Behçet's disease,” European Journal of Dermatology, vol. 16, no. 2, pp. 146–150, 2006. View at Scopus